MSD is spinning off products from its women’s health, legacy brands, and biosimilar franchises into a new, independent, publicly traded company called Organon

Save Print

February 17, 2021 5:34 pm +00:00

News Release

MSD is spinning off products from its women’s health, legacy brands, and biosimilar franchises into a new, independent, publicly traded company called Organon

London: February 2021; MSD known as Merck & Co. Inc, of Kenilworth, New Jersey in the US and Canada will be spinning-off a new, independent, publicly traded company called Organon & Co., which will focus on developing, manufacturing and marketing products from MSD’s current women’s health, trusted legacy brands, and biosimilars businesses. The spinoff, which is expected to be completed late in the second quarter of 2021, will allow each company the opportunity to drive increased responsiveness to the needs of their patients and customers and achieve faster growth through focused investment and fit-for-purpose operating models.

David Peacock, UK and Ireland Managing Director, MSD says, “We have made the decision to separate into two growth companies: MSD and Organon. This decision will allow MSD to move closer to its aspiration of being the premier research-intensive biopharmaceutical company, while also prioritising a set of products at Organon that are important to public health and the patients who rely on them. MSD will continue to focus on its key pillars of oncology, vaccines, hospital and animal health, while remaining fully committed to investing in research and development. As a premier research-intensive biopharmaceutical company, MSD will continue to advance the prevention and treatment of diseases that threaten people and communities around the world.”

Organon, will be fuelled by its leading contraceptives and fertility businesses and will invest in innovations that support the distinct healthcare needs of women. In addition, the company will focus on its biosimilars portfolio in oncology and inflammatory diseases, whilst also maximising the value of its trusted dermatology, pain, respiratory and cardiovascular portfolio in countries around the world where there is still a great need for these treatments.

If you are interested in receiving further information please contact the MSD, external affairs team at: externalaffairs_uk@msd.com.

About MSD

For more than 125 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.msd-uk.com and connect with us @MSDintheUK on Twitter, Instagram, LinkedIn, YouTube and Facebook.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2019 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

GB-NON-03942